Trial Profile

A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions
Acronyms CAELYX

Most Recent Events

07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
01 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
31 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com